Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by CROSSJECT
Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
August 22, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment
August 19, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject achieves key ZEPIZURE® manufacturing milestone
July 18, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference
July 15, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine
July 10, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study
June 26, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America
June 12, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject announces highly successful closing of its €8 million rights offering
June 04, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
May 30, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe
May 02, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject reports audited financial results for 2023
April 25, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject advances in its U.S. Strategy and reports Financial Results for 2023
April 02, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject gender equality score reaches 96/100 in 2024
March 08, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject obtains a financing up to €12 million, in two tranches
February 27, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject provides strategic update on priorities for 2024
February 06, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CET
February 01, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject to present at Biotech Showcase on January 9 at 16:30 PT
January 09, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
January 04, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject signs ZEPIZURE® commercialization agreement for northern Europe
December 22, 2023
From
CROSSJECT
Via
GlobeNewswire
Crossject announces initiation of coverage by ODDO BHF
November 28, 2023
From
CROSSJECT
Via
GlobeNewswire
Crossject reports financial results and business highlights for first half of 2023
September 26, 2023
From
CROSSJECT
Via
GlobeNewswire
Crossject announces significant improvement in Gaïa ESG rating
September 11, 2023
From
CROSSJECT
Via
GlobeNewswire
Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizures
September 05, 2023
From
CROSSJECT
Via
GlobeNewswire
Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
July 20, 2023
From
CROSSJECT
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.